HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Guardant Health nabs FDA test approval to find patients for Boehringer's new cancer drug

Boehringer Ingelheim's Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared its liquid biopsy test, Guardant360 CDx.

By FierceBiotech · Jun 14, 2026 · via FierceBiotech
Guardant Health nabs FDA test approval to find patients for Boehringer's new cancer drug

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Regulatory tracker: Novo's oral GLP-1 picks up UK approval
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
Jun 14, 2026
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
The WeekFierceBiotech ↗
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
Jun 14, 2026
STAT’s focus: Obesity drugs crowd pipeline as peptides gain ground
The WeekBriefing
STAT’s focus: Obesity drugs crowd pipeline as peptides gain ground
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…
Jun 14, 2026